Source Count: 14 | Weighted Score: 34 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 15, 2026
Keywords: drug discovery, pharmacology, ethnobotany, natural products, rational drug design, high-throughput screening, aspirin, penicillin, quinine, traditional medicine, pharmaceutical development, clinical trials, structure-activity relationship, AI drug design, bioprospecting
Category Tags: medicine and healing traditions
Cross-References: X_4_15 — Addiction Medicine · Y_1_01 — Altered States & Psychedelics · ZB_1_01 — Animal Cognition

QUICK SUMMARY

Drug discovery is the process by which new therapeutic compounds are identified, developed, and brought to clinical use. The field has evolved through three major paradigms: (1) ethnobotanical/traditional knowledge — most drugs before 1900 derived from plants identified by indigenous healers (quinine from Cinchona bark, morphine from opium poppy, aspirin from willow bark); (2) empirical screening — the 20th-century approach of systematically testing chemical compounds against disease targets (penicillin, sulfonamides, antivirals); and (3) rational design — using molecular biology, structural biology, and computational methods to design drugs targeting specific biological mechanisms (imatinib for CML, HIV protease inhibitors). David Newman and Gordon Cragg (2020) documented that between 1981 and 2019, approximately 49.2% of all newly approved drugs were derived from or inspired by natural products. The modern pipeline — from target identification through Phase III clinical trials to regulatory approval — takes on average 10–15 years and costs $1–2 billion per approved drug, raising urgent questions about access, pricing, and the devaluation of traditional knowledge that contributed to many foundational discoveries.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Natural Products as the Foundation of Pharmacology

• Evidence: KEY FINDING Newman and Cragg (2020) analyzed all 1,881 new drugs approved worldwide between 1981 and 2019 and found that 49.2% were natural products, derived from natural products, or natural product-inspired. The figure rises to ~64% for anti-cancer agents and ~78% for antibacterials. Key examples: morphine (isolated by Friedrich Sertürner, 1804, from Papaver somniferum), quinine (from Cinchona bark, used by Quechua peoples of Peru for malaria), aspirin (acetylsalicylic acid, synthesized by Felix Hoffmann at Bayer, 1897, derived from willow bark salicin used since antiquity), and paclitaxel/Taxol (from Pacific yew Taxus brevifolia, discovered by Monroe Wall and Mansukh Wani, 1971).
• Primary Source: Newman, David J., and Gordon M. Cragg. "Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019." Journal of Natural Products 83.3 (2020): 770–803

1.2 Penicillin and the Antibiotic Revolution

• Evidence: Alexander Fleming observed the antibacterial properties of Penicillium notatum mold on September 3, 1928, at St. Mary's Hospital, London. Howard Florey and Ernst Boris Chain at Oxford developed penicillin for clinical use, first treating a patient (Albert Alexander) on February 12, 1941. Mass production by Pfizer and other American firms during World War II saved an estimated millions of lives. Fleming, Florey, and Chain shared the 1945 Nobel Prize in Physiology or Medicine. KEY FINDING Fleming presciently warned in his 1945 Nobel lecture that bacterial resistance would emerge from misuse — a prediction now fully realized.
• Primary Source: Fleming, Alexander. "On the Antibacterial Action of Cultures of a Penicillium." British Journal of Experimental Pathology 10.3 (1929): 226–236

1.3 The Modern Drug Pipeline

• Evidence: The contemporary drug development pipeline includes: target identification → lead discovery (high-throughput screening of compound libraries, typically 1–2 million compounds) → lead optimization → preclinical studies (in vitro, animal models, toxicology) → Phase I clinical trials (safety, 20–100 subjects) → Phase II (efficacy, 100–500 subjects) → Phase III (confirmation, 1,000–5,000 subjects) → regulatory review (FDA/EMA) → post-market surveillance. DiMasi et al. (2016) estimated the average capitalized cost at $2.6 billion per approved drug (including failures). The overall probability of a compound entering Phase I reaching approval is approximately 9.6%.
• Primary Source: DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. "Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs." Journal of Health Economics 47 (2016): 20–33

1.4 Rational Drug Design: Imatinib as Paradigm

• Evidence: KEY FINDING Imatinib (Gleevec), developed by Brian Druker and Nicholas Lydon and approved by the FDA on May 10, 2001, was the first successful rationally designed small-molecule drug — targeting the BCR-ABL tyrosine kinase fusion protein specific to chronic myeloid leukemia (CML). It transformed CML from a rapidly fatal disease (median survival ~5 years) to a manageable chronic condition (10-year survival >80%). Imatinib demonstrated the viability of the rational design paradigm: understanding the molecular target, designing a specific inhibitor, and achieving clinical transformation.
• Primary Source: Druker, Brian J., et al. "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia." New England Journal of Medicine 344.14 (2001): 1031–1037

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Ethnobotanical Knowledge and Bioprospecting Ethics

• Evidence: Indigenous knowledge systems have guided the discovery of numerous drugs — the rosy periwinkle (Catharanthus roseus), used in Malagasy traditional medicine, yielded vinblastine and vincristine (childhood leukemia drugs) for Eli Lilly (1960s); the San people's traditional appetite suppressant from Hoodia gordonii was commercialized without consent. The Convention on Biological Diversity (CBD, 1992) and the Nagoya Protocol (2010) established frameworks for benefit-sharing from genetic resources and traditional knowledge. KEY FINDING Despite these frameworks, enforcement remains weak, and the term "biopiracy" — coined by Pat Mooney (1993) — describes the ongoing extraction of traditional knowledge without fair compensation.
• Counter-Argument: Paul Oldham et al. (2014) note that tracing the chain of knowledge from traditional use to commercial drug is often complex, and that many "ethnobotanical leads" fail in development, complicating benefit-sharing calculations.

2.2 AI-Driven Drug Discovery

• Evidence: Machine learning and deep learning models are increasingly applied to drug discovery: predicting protein structures (AlphaFold, John Jumper et al., 2021), generating novel molecular structures (generative adversarial networks), and screening virtual compound libraries. Insilico Medicine (Hong Kong) used AI to identify a novel anti-fibrotic compound (INS018_055) that reached Phase II clinical trials in 2023 — reportedly the first AI-discovered drug to advance this far. Andrew Hopkins (2022) argued AI could reduce preclinical timelines by 2–4 years.
• Counter-Argument: Derek Lowe (2023) cautions that AI drug discovery has been over-hyped — computational screening has existed since the 1990s, and the fundamental challenge of clinical translation (toxicity, pharmacokinetics, patient variability) remains unaddressed by in silico methods.

2.3 The Antibiotic Resistance Crisis

• Evidence: The WHO declared antibiotic resistance one of the top 10 global health threats (2019). Jim O'Neill's UK government-commissioned Review on Antimicrobial Resistance (2016) projected that by 2050, drug-resistant infections could cause 10 million deaths annually (exceeding cancer) and cost $100 trillion in cumulative GDP. Only 2 new antibiotic classes have been approved since 2000 (daptomycin and oxazolidinones), as pharmaceutical companies have largely abandoned antibiotic R&D due to low profitability.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Psychedelic-Assisted Therapy as New Drug Class

• Evidence: Psilocybin, MDMA, and ketamine are in advanced clinical trials for treatment-resistant depression, PTSD, and anxiety. MAPS (Multidisciplinary Association for Psychedelic Studies) conducted Phase III trials for MDMA-assisted therapy for PTSD (2021). The FDA denied approval for MDMA therapy in August 2024 citing methodological concerns, but psilocybin remains in Phase III for depression. Whether psychedelics will constitute a new drug class or remain niche therapeutic tools is uncertain.

RETRACTED - [RETRACTED SOURCE NOTE] The pooled phase 2 analysis underpinning much of the MDMA-PTSD evidence base — Mithoefer et al. (2019), Psychopharmacology (DOI 10.1007/s00213-019-05249-5) — was retracted by the journal on August 10, 2024 (retraction notice DOI: 10.1007/s00213-024-06666-x). Reasons cited included concerns about data, human-subject welfare, conflicts of interest, ethical violations by an author, and IRB/IACUC compliance failures. The retraction is a significant factor in the FDA's August 2024 non-approval decision and weakens (but does not eliminate) the broader case for MDMA-assisted therapy.

3.2 The Ocean as Untapped Pharmaceutical Source

• Evidence: Marine natural products — from sponges, tunicates, mollusks, and marine microorganisms — have yielded several approved drugs (ziconotide from cone snails, eribulin from the sponge Halichondria okadai). Less than 5% of marine microorganisms have been cultured, suggesting vast unexplored chemical diversity. Whether ocean bioprospecting will yield the next generation of therapeutics remains speculative but promising.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Pharmaceutical Companies Suppress Natural Cures

• Evidence: The claim that pharmaceutical companies systematically suppress effective natural remedies to protect drug profits oversimplifies a complex reality. Some natural products (turmeric, cannabis, various botanicals) have genuine therapeutic properties under investigation, while others lack clinical evidence. The pharmaceutical industry's incentive structure does favor patentable synthetic compounds over unpatentable natural products, but this reflects economic structures rather than active suppression of proven cures. DEBUNKED as a conspiracy, though the economic incentive problem is real and structurally significant.

Counter-Arguments & Criticisms

The drug discovery enterprise faces structural critiques: (1) Marcia Angell (2004) argued that pharmaceutical companies spend more on marketing than R&D, and that many "new" drugs are me-too variants rather than genuine innovations; (2) the "valley of death" between academic discovery and clinical translation wastes billions in public research funding; (3) drug pricing — imatinib costs ~$150,000/year in the US vs. ~$400 as a generic in India — raises questions about whether the current IP-driven model serves public health; (4) the devaluation of indigenous ethnobotanical knowledge that founded the field remains an unresolved ethical problem.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Newman, David J.; Gordon M | 2020 | "Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019" | Journal of Natural Products | ∅ | 83.3::770–803 | Cragg | ∅ | doi:10.1021/acs.jnatprod.9b01285 | ∅ | ∅ | ∅
2. Fleming, Alexander | 1929 | "On the Antibacterial Action of Cultures of a Penicillium" | British Journal of Experimental Pathology | ∅ | 10.3::226–236 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
3. Druker, Brian J., et al | 2001 | "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase" | New England Journal of Medicine | ∅ | 344.14::1031–1037 | ∅ | ∅ | doi:10.1056/NEJM200104053441401 | ∅ | ∅ | ∅
4. DiMasi, Joseph A., Henry G | 2016 | "Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs" | Journal of Health Economics | ∅ | 47::20–33 | Grabowski, and Ronald W | ∅ | doi:10.1016/j.jhealeco.2016.01.012 | ∅ | ∅ | Hansen
5. O'Neill, Jim | 2016 | ∅ | Tackling Drug-Resistant Infections Globally: Final Report and Recommendations | ∅ | ∅ | London: Review on Antimicrobial Resistance | ∅ | ∅ | ∅ | ∅ | ∅
6. Angell, Marcia | 2004 | ∅ | The Truth About the Drug Companies: How They Deceive Us and What to Do About It | ∅ | ∅ | New York: Random House | ∅ | isbn:9780375508462 | ∅ | ∅ | ∅
7. Jumper, John, et al | 2021 | "Highly Accurate Protein Structure Prediction with AlphaFold" | Nature | ∅ | 596.7873::583–589 | ∅ | ∅ | doi:10.1038/s41586-021-03819-2 | ∅ | ∅ | ∅
8. Wall, Monroe E.; Mansukh C | 1995 | "Camptothecin and Taxol: Discovery to Clinic" | Cancer Research | ∅ | 55.4::753–760 | Wani | ∅ | ∅ | ∅ | ∅ | ∅
9. Cragg, Gordon M.; David J | 2005 | "Biodiversity: A Continuing Source of Novel Drug Leads" | Pure and Applied Chemistry | ∅ | 77.1::7–24 | Newman | ∅ | doi:10.1351/pac200577010007 | ∅ | ∅ | ∅
10. Oldham, Paul, Stephen Hall; Oscar Forero. e78737 | 2013 | "Biological Diversity in the Patent System" | PLoS ONE | ∅ | 8.11:: | ∅ | ∅ | doi:10.1371/journal.pone.0078737 | ∅ | ∅ | ∅
11. Drews, Jürgen | 2000 | "Drug Discovery: A Historical Perspective" | Science | ∅ | 287.5460::1960–1964 | ∅ | ∅ | doi:10.1126/science.287.5460.1960 | ∅ | ∅ | ∅
12. Swinney, David C.; Jason Anthony | 2011 | "How Were New Medicines Discovered?" | Nature Reviews Drug Discovery | ∅ | 10.7::507–519 | ∅ | ∅ | doi:10.1038/nrd3480 | ∅ | ∅ | ∅
13. Hopkins, Andrew L | 2008 | "Network Pharmacology: The Next Paradigm in Drug Discovery" | Nature Chemical Biology | ∅ | 4.11::682–690 | ∅ | ∅ | doi:10.1038/nchembio.118 | ∅ | ∅ | ∅
14. Mithöfer, Michael C., et al. . Psychopharmacology on August 10, 2024 for ethics violations, IRB/IACUC compliance failures; conflicts of interest | 2019 | "MDMA-Assisted Psychotherapy for Treatment of PTSD" | Psychopharmacology | by | 236.9::2735–2745 | ∅ | ∅ | retraction-doi:10.1007/s00213-024-06666-x.**, doi:10.1007/s00213-019-05249-5 | ∅ | RETRACTED | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 17, 2026 (retraction tag added for source [14] — Mithoefer et al. 2019 retracted by Psychopharmacology Aug 10, 2024).

Corrections

• The Truth About the Drug Companies: How They Deceive Us and — ISBN corrected from 9780375508468 to 9780375508462, verified against Open Library (The truth about the drug companies, Marcia Angell). The previous number failed its check digit.